CellArtgen offers a biomaterial technology platform that provides drug and vaccine development services. CellArtgen’s vision is to innovate in the field of regenerative medicine through the fusion of organoid and biomaterial technologies. Their mission is to provide new solutions to replace existing methods in drug discovery, promoting ethical alternatives to animal testing models.

A noteworthy aspect of CellArtgen is their organoid disease model-based drug evaluation service, which offers a meticulous design to facilitate the study of intractable diseases. They have also been recognized by the South Korean Ministry of Trade, Industry and Energy and the Ministry of SMEs and Start-ups.